• Oxurion: Interim analysis for KALAHARI trial planned by year-end 2022 with full top-line data expected in second half of 2023

    Monday November 21st 2022

  • Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia

    Tuesday November 15th 2022

  • Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON

    Tuesday November 15th 2022

  • Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)

    Tuesday October 25th 2022

  • Mithra announces positive preclinical data demonstrating Estetrol’s efficacy in wound healing

    Wednesday October 12th 2022

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    Thursday September 29th 2022

  • reMYND identifies novel target and small molecules with potential to halt and reverse disease progression in Huntington’s disease through oral administration

    Wednesday August 31st 2022

  • Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial

    Monday August 1st 2022

  • Your news here?

  • Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study and reports disease-modifying profile for Short Term DSR

    Tuesday July 19th 2022

  • ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

    Tuesday July 5th 2022

  • MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis

    Tuesday June 28th 2022


Strategic Partners